INTRODUCTION
============

The prevalence of obesity is increasing globally and this condition predisposes towards diseases such as type 2 diabetes mellitus (T2DM), cardiovascular disease, degenerative joint disease, and certain types of cancer. Therefore, it is considered to be one of the principal global health problems. These worldwide trends are also reflected in Korea. According to the Organization for Economic Co-operation and Development (OECD) Health Data (2014) \[[@B1]\], the prevalence of obesity in Korea is lower than in other OECD countries, but it has substantially increased in recent years. According to a 2016 obesity fact sheet published by the Korean Society for the Study of Obesity \[[@B2]\], the prevalence of obesity increased from 28.7% in 2006 to 32.4% in 2015, and the prevalence of class II obesity was 4.8% in 2015, although the criteria used are different from those used in the Western world. The prevalence of obesity has increased particularly among people aged between 20 and 40 years.

Obesity is a major risk factor for T2DM, so an increase in the prevalence of T2DM can also be predicted. In addition, patients with diabetes have a higher prevalence of obesity than the non-diabetic population, so treatment of overweight and obesity is a key therapeutic aim for patients with T2DM \[[@B3]\]. Recently, the 2nd Diabetes Surgery Summit (DSS-II) and leading diabetes organizations issued a joint statement on metabolic surgery as part of the treatment algorithm for T2DM. This suggested that metabolic surgery should be recommended as an option for the treatment of T2DM in appropriate surgical candidates with class III obesity (body mass index \[BMI\] \>40 kg/m^2^ in Caucasian, \>37.5 kg/m^2^ in Asian people), regardless of their level of glycemic control or the complexity of the glucose-lowering regimens being used, and in patients with class II obesity (BMI 35.0 to 39.9 kg/m^2^ in Caucasian, 32.5 to 37.59 kg/m^2^ in Asian people) with inadequately controlled hyperglycemia despite appropriate lifestyle and pharmacological therapy \[[@B4]\]. In the Korean Diabetes Association (KDA) clinical practice guidelines of 2015 \[[@B5]\], patients of BMI \>35 kg/m^2^ are recommended to undergo surgery. However, although many guidelines now recommend surgical treatment for obese patients with T2DM, additional factors must be taken into account before pursuing this strategy. Therefore, this article reviews the indications for metabolic surgery and specific considerations for individual patients, with a specific focus on Korea.

BARIATRIC AND METABOLIC SURGERY FOR PATIENTS WITH T2DM IN KOREA
===============================================================

Although bariatric surgery was developed as a treatment strategy for morbid obesity, many studies have shown that it can improve glycemic control and other metabolic parameters. The first report that surgery could ameliorate hyperglycemia was published in 1955 by Friedman \[[@B6]\]. This showed that T2DM was brought under control after subtotal gastrectomy for the treatment of peptic ulcer disease. In 1984, bariatric surgery was reported to improve glucose tolerance in insulin-treated patients \[[@B7]\], and then in 1995 Pories et al. \[[@B8]\] reported that it improved glucose homeostasis and promoted T2DM remission, suggesting that surgery could be a very effective therapy for adult-onset T2DM. Since then, many studies have demonstrated improvements in glycemia and other metabolic parameters after surgery, and this has led to the issue of therapeutic guidelines, such as those from the American Diabetes Association (ADA) \[[@B4][@B5]\], which suggest that surgery is an option for obese patients with T2DM. In addition, the recommended name for this intervention has been changed from bariatric to metabolic surgery \[[@B9]\].

Bariatric surgery was first introduced in Korea in 2003 and it led to weight loss and improvement in obesity-related metabolic comorbidities, including T2DM \[[@B10]\]. Because of a high incidence of gastric cancer in Korea, a large number of gastrectomies are performed here annually, and therefore re-analysis of existing data was used to evaluate the effect of gastrectomy on glycemic control in patients with T2DM. Kang et al. \[[@B11]\] analyzed the effect of gastrectomy on glycemic control using data collected from gastric cancer patients who also had T2DM. These patients achieved BMIs of \<30 kg/m^2^ and less severe diabetes after gastrectomy. Roux-en-Y (RY) esophagojejunostomy and Billroth-II procedures resulted in greater improvements than Billroth-I, and RY esophagojejunostomy resulted in the greatest improvements, suggesting that the specific procedure determines how effective surgery is for the treatment of T2DM. Other studies of gastrectomy patients with T2DM also yielded similar results \[[@B12]\].

Duodenojejunal bypass (DJB) was first performed on non-obese diabetic patients in Korea in 2009 by Hong et al. \[[@B13]\]. His group performed DJB on 25 patients with T2DM and BMI \<25 kg/m^2^. One week after surgery, postoperative 75 g oral glucose tolerance testing suggested significantly improved glycemic control \[[@B13]\], and 1 year later \~40% of patients showed improved glycemic control, but just 9% of patients were in remission \[[@B14]\]. Paik et al. \[[@B15]\] also reported the clinical effects of laparoscopic DJB in non-morbidly obese patients with T2DM, after which \~60% of the patients showed better glycemic control. DJB has been abandoned as a metabolic surgery because of the low remission and improvement rates achieved compared to other procedures, despite its advantages from a nutritional respect. Subsequently, RY gastric bypass and sleeve gastrectomy (SG) were performed in T2DM patients, resulting in acceptable remission and improvement rates. There are summaries of the published studies of metabolic surgery in [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} \[[@B11][@B12][@B15][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25][@B26][@B27][@B28][@B29][@B30][@B31][@B32]\]. Although there are limitations to these, such as short durations of follow-up, the small size of the studies, varying definitions of remission, and various types of surgery, these all resulted in improvements in glycemic control and suggested mechanisms for these effects. The milestones in the development of bariatric/metabolic surgery are depicted in [Fig. 1](#F1){ref-type="fig"}.

FACTORS TO CONSIDER WHEN SELECTING PATIENTS FOR METABOLIC SURGERY
=================================================================

Should patients be selected for metabolic surgery based on their BMI?
---------------------------------------------------------------------

In 1991, the National Institutes of Health (NIH) released its recommendations for bariatric surgery. This statement recommended that patients undergo bariatric surgery if they had BMI \>40 or \>35 kg/m^2^ if accompanied by serious comorbidities \[[@B33]\], and many subsequent guidelines adhered to these recommendations. In 2005, the Asia-Pacific Bariatric Consensus Meeting suggested that the NIH BMI guidelines be lowered to 37 and 32 kg/m^2^ for Asians \[[@B34]\]. However, many studies have since shown that bariatric surgery not only improves body mass, but also the severity of T2DM and its complications \[[@B35]\]. In addition, some studies have elucidated mechanisms; whereby, T2DM can be ameliorated beyond those that are consequences of weight reduction.

In 2011, the International Diabetes Federation included bariatric surgery in its list of approved treatments for T2DM and recommended it for patients with BMI \>35 kg/m^2^ for Caucasians and \>32.5 kg/m^2^ for Asians \[[@B36]\]. Based on these developments, many societies have changed the name used for such interventions from bariatric to metabolic surgery \[[@B9]\]. Recently, DSS-II and six leading international diabetes organizations, namely the ADA, International Diabetes Federation, Chinese Diabetes Society, Diabetes India, European Association for the Study of Diabetes, and Diabetes UK, issued a joint statement on metabolic surgery that recommended it should be an option for the treatment of T2DM in appropriate surgical candidates with class III obesity (BMI ≥40 kg/m^2^), regardless of their glycemic control or the complexity of their glucose-lowering regimens, and also in patients with class II obesity (BMI 35.0 to 39.9 kg/m^2^) and poorly controlled hyperglycemia, even if receiving appropriate lifestyle and medical therapy. Furthermore, it stated that metabolic surgery should also be considered as a therapeutic option for T2DM patients with class I obesity (BMI 30.0 to 34.9 kg/m^2^) and poorly controlled hyperglycemia, if the use of oral or injectable medication had been ineffective. They also recommended that the BMI threshold be 2.5 kg/m^2^ lower for Asian patients \[[@B4]\]. The Clinical Practice Guidelines (2011) issued by the KDA suggested that bariatric surgery be performed on patients with T2DM and BMI \>35 kg/m^2^. However, since 2015 the Clinical Practice Guidelines of the KDA have recommended surgical treatment for patients with T2DM and BMI \>35 kg/m^2^ \[[@B5]\].

Thus, the BMI thresholds for metabolic surgery, the principal factor used to select surgical candidates, have evolved alongside the publication of numerous studies, but there is still concern regarding whether the consideration of BMI alone is sufficient for patient selection. In part, this is because the metabolic outcome varies according to fat distribution \[[@B37]\]. Visceral adiposity is a well-known risk factor for metabolic syndrome. Kim et al. \[[@B18]\] reported that after Roux-en-Y gastric bypass (RYGB) surgery, despite there being no difference in preoperative BMI between patients who went into remission and those who did not, the visceral-to-subcutaneous adipose volume ratio was greater in patients who did not go into remission, suggesting that visceral adiposity is a negative predictor of diabetic remission after RYGB. Importantly, the Asian population has a higher percentage of body fat for a given body mass and is predisposed to abdominal adiposity \[[@B38]\]. Moreover, recent studies have reported that gluteal subcutaneous adipose tissue has a protective effect against cardiometabolic risk factors \[[@B39]\]. These reports thus demonstrate the importance of fat distribution, which BMI does not reflect.

Many studies have shown that the hyperglycemia of obese patients with T2DM was ameliorated even before significant weight loss had occurred \[[@B8][@B40]\], suggesting that there is a mechanism independent of weight loss. If so, metabolic surgery could also have benefits for non-obese patients. Patients with diabetes who underwent gastrectomy for gastric cancer and who had a BMI of \~25 kg/m^2^ showed improved hyperglycemia \[[@B12]\]. In addition, there have been a small number of studies on the effect of bariatric surgery in non-obese diabetic patients. These studies reported amelioration of hyperglycemia, but the remission rate was lower than for obese patients \[[@B14][@B16]\]. Therefore, other factors should be considered for patients with lower BMI. Impaired insulin secretion is also an important pathological feature of T2DM. A study of a large cohort in Chicago showed that 13% of patients with diabetes had a BMI ≤25 kg/m^2^. Compared with their obese counterparts, they were more likely to use insulin and have a history of pancreatitis, suggesting that the lean group had more advanced β-cell failure \[[@B41]\]. Studies of Asian subjects have shown that β-cell function is worse than that of otherwise comparable Caucasian subjects \[[@B42]\]. Indeed, a study of the insulin secretory function of Korean patients with diabetes showed that it was impaired early in the pathogenesis of T2DM \[[@B43]\]. Moreover, cohort studies have shown that progressors to diabetes have more pronounced impairment of β-cell function than non-progressors in the Korean population \[[@B44]\]. Preservation of β-cell function is one of the predictive factors for the remission of diabetes \[[@B45]\]. Therefore, given that Korean patients with T2DM are more likely to have worse β-cell function than severe insulin resistance, it would be sensible to check β-cell function in addition to measuring BMI during surgical candidate selection, especially with regard to the proper timing of the surgery. However, to further assess this suggestion, long-term studies are required. Nevertheless, improvement in β-cell function after metabolic surgery is reported to be the most important factor in achieving remission in T2DM patients with low BMI in Korea. The preoperative C-peptide level does not affect much surgical outcomes, although it tends to be higher in the target-achieved group than in the target non-achieved group; thus, recovery of β-cell function is a more important predictive factor than the preoperative C-peptide level. These findings suggest that metabolic surgery could improve β-cell secretory function \[[@B32]\].

Which procedure is most effective for patients with T2DM?
---------------------------------------------------------

There are four accepted procedures for metabolic surgery: RYGB, adjustable gastric banding (AGB), SG, and biliopancreatic division. The joint statement by the International Diabetes Organization recommends that the choice of procedure is based on the evaluation of the risk-benefit ratio for individual patients because of the lack of randomized controlled trials that have compared surgical outcomes \[[@B4]\]. Among these procedures, RYGB and SG are commonly used in patients with diabetes \[[@B46]\]. However, according to a nationwide survey of bariatric and metabolic surgery, gastric banding is the most common pro-cedure undertaken in Korea. Nevertheless, if patients with diabetes are considered alone, RYGB, mini gastric bypass, and SG were performed much more frequently than AGB \[[@B47]\].

Many studies have shown that RYGB is beneficial and it is a widely accepted procedure. There is a great deal of evidence that RYGB has beneficial effects through restriction of food and calorie intake, altered incretin hormone secretion, altered gut microflora, and bile acid metabolism \[[@B48][@B49]\]. However, because of the high incidence of gastric cancer in Korea, there is concern about its effects on cancer screening. A nationwide survey showed that the number of SG procedures being undertaken has been increasing because they have the advantages of efficacy, relative simplicity, and fewer problems in the long term with malnutrition and other complications, as well as that of avoiding problems with surveillance for gastric cancer in the remaining portion of the stomach. In addition, some studies have reported that SG has direct effects on glucose metabolism that are not secondary to weight loss \[[@B50][@B51]\]. However, there are few data from long-term studies to date.

Recently, new procedures have been introduced for the Asian population. After Rubino and Marescaux \[[@B52]\] reported the use of DJB, other studies reported that its effects did not represent an improvement over conventional surgery \[[@B53]\]. Lee et al. \[[@B54]\] reported the results of the use of a combined SG/DJB procedure. This was similarly or more efficacious than conventional procedures and was accompanied by less malnutrition. Another advantage is the avoidance of the risk of gastric cancer arising from the remaining portion of the stomach \[[@B54]\]. Because a similar situation exists in the Korean population, this approach could be effective here, but the results of further studies are awaited.

PSYCHOLOGICAL AND SOCIAL SUPPORT REQUIREMENTS FOR PATIENTS UNDERGOING METABOLIC SURGERY
=======================================================================================

A recent report showed that the stigma of obesity might result in negative health outcomes, such as weight regain and depression. Indeed, many patients undergoing bariatric surgery might have a long history of weight stigma. Weight stigma has been observed in a healthcare setting, in which it resulted in impaired postsurgery dietary adherence \[[@B55]\]. In addition, candidates for bariatric surgery have similarly high levels of depression to psychotherapy inpatients, but they are perceived as having better mental well-being \[[@B56]\]. According to the report by Brewis et al. \[[@B57]\] on the 2014 Korean National Health and Nutritional Survey (KNHANES) cohort, people with higher body mass in Korea report more symptoms of depression and women, in particular, are at more risk. Such symptoms reduce the quality of life for obese people. However, a number of reports have shown that surgery improved the quality of life and alleviated mental health problems \[[@B56][@B58]\]. Therefore, mental health should be evaluated before and after surgery, considering whether barriers such as weight stigma are present.

Metabolic surgery is a cost-effective treatment for obese people, especially for those with T2DM \[[@B59]\]. According to the KNHANES, many obese people are not financially well off. In the case of the United States, most insurance companies covered bariatric surgery when medical treatment for obesity failed for a certain period. The American Society for Metabolic and Bariatric Surgery recommend \[[@B60]\] that patients seeking surgical treatment should be evaluated based on their BMI and comorbid conditions because the discriminatory, arbitrary practice of insurance-mandated preoperative weight loss causes an unnecessary delay of life-saving treatment and leads to the progression of life-threatening comorbid conditions. However, unlike in Western countries, both surgical treatment and anti-obesity drugs are not covered by insurance in Korea. Thus, a system for the support of obese people, especially those with diabetes, is required.

CONCLUSIONS
===========

There is a consensus that obesity is a significant risk factor for a number of diseases. Many obesity-related diseases, especially T2DM, decrease the quality of life and increase medical costs, resulting not only in health but also in social problems. Therefore, a comprehensive approach is needed to select candidates for metabolic surgery. A number of problems remain to be solved, e.g., despite its potential benefits for obese patients with T2DM, there is still a lack of understanding of metabolic surgery in Korea, which could delay its implementation unnecessarily. Moreover, for the success of metabolic surgery, further studies are needed to establish: (1) the criteria, besides BMI, for patients with T2DM, (2) the effect of metabolic surgery on micro- and macro-complications in the long-term, (3) the timing of surgery, (4) the best procedure for each individual, (5) its long-term effect on nutrition, and (6) its long term safety.
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![A history of bariatric and metabolic surgery. In 1991, the National Institutes of Health (NIH) released the guidelines for bariatric surgery. Since then, based on numerous studies, the guidelines concerning the use of the body mass index (BMI) as an indication for bariatric surgery and metabolic surgery have undergone numerous changes. The important events are highlighted in the blue-colored boxes. ASBS, American Society for Bariatric Surgery; ASMBS, American Society for Metabolic and Bariatric Surgery; DSS, Diabetes Surgery Summit; ADA, American Diabetes Association; IDF, International Diabetes Federation; KSMBS, Korean Society of Metabolic and Bariatric Surgery; DJB, duodenojejunal bypass; APBSG, Asia-Pacific Bariatric Surgery Group; ACMOMS, Asian Consensus Meeting on Metabolic Surgery; IFSO, International Federation for the Surgery of Obesity and Metabolic Disorders; APC, Asia-Pacific Chapter; APMBSS, Asia Pacific Metabolic and Bariatric Surgery Society; KDA, Korean Diabetes Association. ^a^BMI threshold was reduced to 2.5 kg/m^2^ for Asians.](enm-32-307-g001){#F1}

###### A Summary of Previous Publications Regarding the Effect of Gastrectomy on Glycemic Control in Patients with Gastric Cancer
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                           No.    Type of surgery         BMI, kg/m^2^   Follow- up, mo   Definition of remission                                                                                           Remission rate, %
  ------------------------------- ------ ----------------------- -------------- ---------------- ----------------------------------------------------------------------------------------------------------------- -------------------
  Kim et al. (2012) \[[@B17]\]    403    B-I, B-II, RY           24.7±3.0       33.7±20.6        Euglycemia or HbA1c \<6.0% without medication                                                                     15.1

  Kang et al. (2012) \[[@B11]\]   75     B-I, B-II, RY           23.8±2.9       35.0±25.9        No medication, Normal FBS, HbA1c \<6.0%                                                                           B-I: 0\
                                                                                                                                                                                                                   B-II: 22.2\
                                                                                                                                                                                                                   RY:23.5

  Lee et al. (2012) \[[@B12]\]    0229   B-I, B-II, RYGJ, RYEJ   23.9±3         12               FBS must be \<100 mg/dL and the patient no longer taking antidiabetic medication or insulin for at least 1 year   B-I: 15.1\
                                                                                                                                                                                                                   B-II: 20.3\
                                                                                                                                                                                                                   RYGJ: 20\
                                                                                                                                                                                                                   RYEJ: 50

  An et al. (2013) \[[@B19]\]     64     B-I, B-II, TG with RY   24.7±3.4       12               No medication and FBS \<126 mg/dL and HbA1c \<6.0%                                                                B-I: 0\
                                                                                                                                                                                                                   B-II: 6.2\
                                                                                                                                                                                                                   TG: 8.3

  Kim et al. (2013) \[[@B20]\]    15     RYGJ, RYEJ              25.2±3.4       12.5±5.5         HbA1c \<6.0% without medication                                                                                   78.6

  Kwon et al. (2014) \[[@B21]\]   49     B-I, B-II               \<30           24               FBS \<126 mg/dL and HbA1c of \<6.5% for at least 1 year without pharmacotherapy                                   B-I: 39.1\
                                                                                                                                                                                                                   B-II: 47.9

  Park et al. (2015) \[[@B22]\]   90     B-I, B-II, RY           24.8±3.4       24               Normal HbA1c and FBS \<100 mg/dL for at least 1 year in the absence of pharmacotherapy or ongoing procedures      NA

  Kim et al. (2015) \[[@B23]\]    30     Long RYGJ               26.8±3.5       12               HbA1c \<6.5% without antidiabetic medication                                                                      30.0
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are expressed as mean±SD.

BMI, body mass index; B-I, Billroth-I; B-II, Billroth-II; RY, Roux-en-Y; HbA1c, glycated hemoglobin; FBS, fasting blood sugar; RYGJ, Roux-en-Y gastrojejunostomy; RYEJ, Roux-en-Y esophagojejunostomy; TG, total gastrectomy; NA, not applicable.

###### A Summary of the Studies Published on Metabolic Surgery in Korea
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                               No.    Type of surgery                      BMI, kg/m^2^   Follow-up, mo   Definition of remission                                                  Remission rate, %
  ----------------------------------- ------ ------------------------------------ -------------- --------------- ------------------------------------------------------------------------ -------------------
  Kim et al. (2010) \[[@B24]\]        0219   LRYGBP                               50.4±8.7       12--48          HbA1c \<7% without medication                                            71.1

  Kim et al. (2011) \[[@B18]\]        50     RYGB                                 34.5±2.5       12              HbA1c \<6.5% and FBS \<126 mg/dL for 1 year or more without medication   68.0

  Kim et al. (2011) \[[@B16]\]        10     LMGB                                 27.2           6               HbA1c \<7%                                                               70.0

  Paik et al. (2012) \[[@B15]\]       12     LDJB                                 27.9±0.37      12              NA                                                                       NA

  Kim et al. (2012) \[[@B25]\]        22     RYGB                                 32.6±3.3       12              HbA1c \<6.5% and FBS \<126 mg/dL for\                                    73.0
                                                                                                                 1 year or more without medication                                        

  Kim et al. (2013) \[[@B26]\]        57     RYGB                                 34.2±4.1       12              HbA1c \<6.5% and FBS \<126 mg/dL for\                                    70.0
                                                                                                                 1 year or more without medication                                        

  Dixon et al. (2013) \[[@B27]\]^a^          RYGB MGP                             26±3.0         12              HbA1c \<6.0% without medication                                          30.1

  Heo et al. (2013) \[[@B14]\]        31     DJB                                  23.1±1.3       12              HbA1c \<6.0% without medication                                          13.3

  Kwon et al. (2014) \[[@B28]\]       22     RYGB DJB                             27.4±5.3       3               Improved: HbA1c \<7.0% without medication^b^                             45.5

  Kim et al. (2014) \[[@B29]\]        33     RYGB                                 32.9±4.3       24              HbA1c \<6.5% and FBS \<126 mg/dL for\                                    55.0
                                                                                                                 1 year or more without medication                                        

  Kim et al. (2014) \[[@B30]\]        0107   LSAGB                                25.3±3.2       12--36          Therapeutic target: HbA1c \<7%                                           1-Year: 53\
                                                                                                                                                                                          2-Year: 63\
                                                                                                                                                                                          3-Year: 90

  Kim et al. (2014) \[[@B31]\]        12     Laparoscopic single anastomosis GB   25.3±5.2       1               NA                                                                       NA

  Kwon et al. (2017) \[[@B32]\]       15     RYGB                                 26.1           24              Target-achieved: HbA1c \<6.5% without\                                   47
                                                                                                                 medication                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are expressed as mean±SD.

BMI, body mass index; LRYGBP, laparoscopic Roux-en-Y gastric bypass; HbA1c, glycated hemoglobin; RYGB, Roux-en-Y gastric bypass; FBS, fasting blood sugar; LMGB, laparoscopic mini gastric bypass; LDJB, laparoscopic duodenojejunal bypass; NA, not applicable; MGP, mini-gastric bypass; DJB, duodenojejunal bypass; LSAGB, laparoscopic single anastomosis gastric bypass; GB, gastric bypass.

^a^This study included participants in Korea and Taiwan; ^b^Different definition of outcome
